Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating restated by stock analysts at Maxim Group in a report released on Wednesday.

The analysts wrote, “Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.””

Other analysts have also issued reports about the company. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price objective for the company. in a report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Barclays PLC cut their price objective on Teva Pharmaceutical Industries Limited from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Four investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.39.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 14.56% during trading on Wednesday, reaching $16.08. The company had a trading volume of 79,187,782 shares. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $45.85. The stock’s market cap is $16.34 billion. The company has a 50-day moving average price of $16.99 and a 200 day moving average price of $26.97.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.25 EPS. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.31 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/04/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-maxim-group.html.

Several large investors have recently modified their holdings of the company. Perpetual Ltd acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at about $2,865,000. WFG Advisors LP grew its position in shares of Teva Pharmaceutical Industries Limited by 2,650.1% in the second quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock valued at $989,000 after purchasing an additional 28,701 shares during the last quarter. Oak Associates Ltd. OH grew its position in shares of Teva Pharmaceutical Industries Limited by 0.6% in the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock valued at $12,621,000 after purchasing an additional 2,114 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at about $373,000. Finally, Sterneck Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 5.4% in the second quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock valued at $4,382,000 after purchasing an additional 6,702 shares during the last quarter. 56.77% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.